INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 417m ago
HOUSE PTR17m ago
SEC 13F17m ago
ROBINHOOD CHAIN17m ago
Corporate insider
TR

Tsuchimoto Kim R

DirectorCIK 0001333516

EDGAR filingsOpen in network
Disclosed transactions10
Buys / sells0 / 4
Max Insider Score25
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
25
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$84K
1,199 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Monopar TherapeuticsDirector · Nov 4, 2026
0
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M
$26K
856 sh
Nov 4, 2026
Nov 4, 2026
traded Nov 4, 2026
+0d
SEC FORM 4

Evidence

7
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M$28K
2,035 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

17
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$92K
1,295 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

21
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$71K
996 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

0
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M$36K
1,199 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

7
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M—
1,199 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

3
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M—
856 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

7
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Option exercise · 10b5-1 plan
M—
2,035 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

18
TR
Tsuchimoto Kim RDirector
MNPRMonopar Therapeutics
Open-market sale · 10b5-1 plan
SELL$43K
600 sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence